Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
4353197 | Neuroscience Research | 2006 | 5 Pages |
Abstract
The neuromuscular weakness associated with myasthenia gravis (MG) can be transiently relieved by pharmacological inhibitors of acetylcholinesterase (AChE). Here, we expand the anticholinesterase repertoire to include 2′-O-methyl-protected antisense oligonucleotides targeted to AChE mRNA (EN101). Using stimulated-single fiber electromyography, we show that EN101 treatment of rats with experimental autoimmune myasthenia gravis (EAMG), improved the mean consecutive difference (MCD) and blocking for 24 h. This treatment was more efficient than pyridostigmine and was accompanied by marked improvement in stamina and clinical profile.
Keywords
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
Neli Boneva, Yasmine Hamra-Amitay, Itzhak Wirguin, Talma Brenner,